Main clinical studies of Bruton’s tyrosine kinase inhibitors (BTKis)
Type de matériel :
Nous n'avons pas d'exemplaire de ce document
86
Quality of life evaluation is crucial in therapeutic trials in hematology, but is not yet recognized as the only true patient-centered primary endpoint. For chronic lymphocytic leukemia patients, how can we move beyond focusing solely on progression-free survival to truly consider overall survival with good quality of life?
Réseaux sociaux